Welcome to our dedicated page for eXoZymes SEC filings (Ticker: EXOZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
eXoZymes Inc. SEC filings document a Nevada biotechnology issuer with common stock listed on the Nasdaq Capital Market under the symbol EXOZ. The filing record is centered on Form 8-K Item 8.01 current reports that furnish investor presentations, press releases, and exhibit materials.
These filings disclose company communications about the exozyme cell-free biomanufacturing platform, NCTx business materials, NCT production scale-up, commercial-readiness updates, and capital-markets presentation materials associated with securities offering activity. They also identify the registered common stock class, exchange listing, exhibit filings, and formal signatures required under Exchange Act reporting.
EXOZYMES INC. reported that Chief Commercial Officer Perriman Damien Alan filed an initial Form 3 as an officer of the company. This filing establishes his status as an insider subject to ongoing ownership and transaction reporting requirements, but it does not list any current holdings or transactions.
Perriman Damien Alan reported acquisition or exercise transactions in this Form 4 filing.
EXOZYMES INC. Chief Commercial Officer Damien Alan Perriman received a grant of 8,887 shares of common stock on 2026-04-01. The shares were awarded as a compensation-related grant at a reported price of $8.44 per share, rather than through an open-market purchase or sale.
Opgenorth Paul Hideo reported acquisition or exercise transactions in this Form 4 filing.
EXOZYMES INC. reported that Vice President of Development Paul Hideo Opgenorth received a grant of 3,999 shares of common stock on April 1, 2026 at a price of $8.44 per share. Following this compensation-related award, his direct holdings increased to 645,149 shares of EXOZYMES common stock.
Exozymes Inc. Vice President-Finance Nawaz Fouad received a stock award of 5,999 shares of common stock. The shares were granted at a value of $8.44 per share and are reported as a grant, award, or other acquisition rather than an open-market purchase. Following this award, his directly held common stock position increased to 9,488 shares.
Korman Tyler Paz reported acquisition or exercise transactions in this Form 4 filing.
Exozymes Inc. reported that Chief Scientific Officer Tyler Paz Korman received a stock grant of 5,332 shares of common stock on April 1, 2026, at a value of $8.44 per share. Following this compensation-related award, Korman directly holds a total of 730,623 common shares.
eXoZymes Inc. filed a current report to make public an updated Investor Presentation for its NCTx business as of March 30, 2026. The company characterizes this under an Other Events item, using the 8-K to furnish the new presentation as Exhibit 99.1.
eXoZymes Inc. (EXOZ) is a pre‑revenue, development‑stage company building a cell‑free biomanufacturing platform based on AI‑engineered enzymes called exozymes. The technology aims to produce high‑value small molecules for nutraceuticals, pharmaceuticals, and biofuels more efficiently and sustainably than traditional petrochemistry, natural extraction, or cell‑based synthetic biology.
The company is initially focused on “nutraceutical‑with‑pharmaceutical‑potential” compounds and on isobutanol for sustainable aviation fuel. A lead program, N‑trans‑caffeoyltyramine (NCT), has shown strong preclinical metabolic effects and is being advanced as a branded nutraceutical ingredient with potential future drug analogs. eXoZymes’ model centers on spin‑outs, joint ventures, and licensing to partners who provide capital, manufacturing, and market access.
From inception through December 31, 2025, eXoZymes received $17.7 million in grants that helped fund platform development but expects to rely more on commercialization going forward. As of late March 2026, market capitalization based on non‑affiliate holdings was about $38.4 million, with 8.48 million common shares outstanding, underscoring its early‑stage status and execution risk.
Exozymes Inc. filed a Form 8-K to inform investors that it issued a press release dated January 29, 2026. The release announces the advancing commercial readiness of the company’s initial NCT pilot run, indicating progress toward moving this early-stage initiative closer to potential commercial use.
eXoZymes Inc. has put in place a shelf registration to offer up to $50,000,000 of securities, including common stock, preferred stock, debt securities, warrants, subscription rights and units, to be issued in one or more future offerings. The exact terms, pricing and mix of these securities will be set in separate prospectus supplements for each transaction and may involve sales directly by the company, through underwriters, dealers or agents, or a combination of these methods.
The company states that, unless specified otherwise in a supplement, net proceeds will be used for general corporate purposes and working capital, which may include capital spending, research and development, regulatory and clinical trial costs, technology or asset acquisitions and business expansion. eXoZymes’ common stock trades on the Nasdaq Capital Market under the symbol EXOZ, and as of January 23, 2026, there were 8,400,258 shares of common stock issued, with a closing price of $11.85 per share on that date.